Cabaletta Bio, Inc. (CABA)

11,26 -0,96 (-7,86%) Al cierre: 04:00PM EDT

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
https://www.cabalettabio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 101

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Steven A. Nichtberger M.D.	Co-Founder, Chairman, CEO & President	1,02M	N/A	1961
Dr. Gwendolyn K. Binder Ph.D.	President of Science & Technology	722,62k	N/A	1975
Dr. David J. Chang FACR, M.D., M.P.H.	Chief Medical Officer	721,85k	N/A	1963
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/A	N/A	N/A
Mr. Anup Marda M.B.A.	Chief Financial Officer	548,2k	N/A	1978
Dr. Samik Basu M.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Michael Gerard J.D.	General Counsel & Secretary	N/A	N/A	1980
Ms. Heather Harte-Hall M.Sc.	Chief Compliance Officer	N/A	N/A	N/A
Ms. Martha O'Connor	Chief Human Resources Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Cabaletta Bio, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 5; Tablero: 9; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.